As an extensively recognized oncogene, FRAT1 is overexpressed in ovarian cancer 42, non-small cell lung cancer 43, pancreatic cancer 44, gastric cancer 45, and liver cancer 46, and it is associated with poor clinical prognosis. Here, FRAT1 is linked to ovarian carcinoma.